Abstract:Introduction & objective: 3 M Syndrome is a rarely encountered autosomal recessive syndrome characterized by low birth weight, severe postnatal growth deficiency, and minor dysmorphic abnormalities. 3 M-related short stature has been attributed to the resistance to growth hormone (GH) to a certain extent rather than to GH deficiency. The resistance to GH, on the other hand, has been associated with impaired protein scaffolding, transport, and p53-mediated apoptosis at the IGF-1 post-receptor pathway. In this context, the objective of this study is to evaluate the clinical, laboratory, and genetic characteristics of the patients with 3 M syndrome, detect the mutations frequently observed in these patients, and assess their response to GH treatment. Material&methods: The sample of this single-center study consisted of patients diagnosed with 3 M syndrome based on genetic tests between 2007 and 2021. Patients' clinic, laboratory, and genetic characteristics pertaining to the time of admission and follow-up were recorded. All patients except one underwent a growth hormone stimulation test (GHST) (Levo-dopa or insulin tolerance test). Insulin-like growth factor (IGF) generation test was performed on those with sufficient GHST results (0.1 mg/kg/day for four days). Results: The median age of the patients, five females and three males, was 2.8 (0.25-8.12) years at admission. All but one patient were small for gestational age (SGA). The patient with normal birth weight was the baby of a diabetic mother. Obscurin-like 1 (OBSL1) variant was detected in all cases. The median height standard deviation score (SDS) at admission was -4.94 ((-5.63)- (-3.27)) SDS, and the median midparenteral height SDS was -1.27 SDS ((-3.1)- (0.34)). All patients were prepubertal at admission. The GHST response was sufficient in five cases. IGF generation test was performed in three cases. Seven patients received GH therapy (35-57 μg/kg/day). Five of these patients discontinued GH therapy since their growth velocity (GV) fell below normal during treatment. In addition, one case discontinued GH therapy because her IGF-1 value was>2 SDS, and another case received gonadotropin-releasing hormone (GnRH) analogs together with GH therapy. The median age and height SDS of the patients were 10.1 (1.79-18) years and -5.09 SDS ((-7.11)- (2.45)), respectively, as of the last follow-up visit. The height SDS values of the two cases that reached the final height were -7.11 SDS and -3.39 SDS. There were no side effects of GH treatment. Conclusion: The study findings indicated a good GV during the early stages of the long-term GH treatment administered to patients with 3 M syndrome. However, response to GH therapy decreased in the following years, and the desired improvement in height SDS could not be achieved in patients who reached their final heights. Taken together with the literature data, it has been concluded that initiating GH therapy in the prepubertal period provided better outcomes than after puberty.

3-M slender-boned nanism. An intrauterine growth retardation syndrome

A rare cause of syndromic short stature: 3M syndrome in three families

Skeletal Phenotype in Mulibrey Nanism, A Monogenic Skeletal Dysplasia With Fibrous Dysplasia

3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient

Clinical Features of Girls with Short Stature among Inv (9), Turner (45, X) and Control Individuals

Triple X Syndrome with Short Stature: Case Report and Literature Review.

Triple X SyndromewithShort Stature: Case Reportand Literature Review

3M syndrome patient with a novel mutation: A case report

New X-linked mental retardation (XLMR) syndrome with distinct facial appearance and growth retardation

3C Syndrome With A Predominance Of Facial Changes: A Case Report.

Growth Concerns in Coffin–Lowry Syndrome: A Case Report and Literature Review

3M syndrome: Evaluating the clinical and laboratory features and the response of the growth hormone treatment: Single center experience

Studies of microcephalic primordial dwarfism II: the osteodysplastic type II of primordial dwarfism

Prenatal Phenotypic Expansion: A Fetus with Neurodegeneration with Developmental Delay, Early Respiratory Failure, Myoclonic Seizures, and Brain Abnormalities (NDDRSB) and MED11 Variants.

A Novel CEP57 Variant Associated with Mosaic Variegated Aneuploidy Syndrome in a Chinese Female Presenting with Short Stature, Microcephaly, Brachydactyly, and Small Teeth

A long way to syndromic short stature

Further expanding the mutational spectrum and investigation of genotype–phenotype correlation in 3M syndrome

Neu Laxova syndrome and megacystis in the first trimester: Broadening the fetal phenotype

Novel OBSL1 Variant in a Chinese Patient with 3M Syndrome and the c.458dupG Mutation May Be a Potential Hotspot Mutation in the Chinese Population

Different Phenotypes of Schimke Immuno-Osseous Dysplasia (SIOD) in Two Sisters with the Same Mutation in the SMARCAL1 Gene

Molecular diagnosis of patients with syndromic short stature identified by trio whole-exome sequencing